Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform
暂无分享,去创建一个
Marco Mora | Barbara Banelli | Irene Vanni | Angela Alama | Erika Rijavec | Carlo Genova | Simona Coco | C. Maggioni | A. Truini | F. Grossi | C. Genova | E. Rijavec | S. Coco | G. Barletta | F. Biello | M. D. Dal Bello | I. Vanni | A. Alama | Francesco Grossi | Anna Truini | Marta Rusmini | Maria Giovanna Dal Bello | Giulia Barletta | Federica Biello | Claudia Maggioni | M. Mora | B. Banelli | M. Rusmini
[1] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[2] Vladimir Makarov,et al. Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel. , 2004, Genome research.
[3] P. Nederlof,et al. A multiplex PCR predictor for aCGH success of FFPE samples , 2005, British Journal of Cancer.
[4] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[5] Rakesh Nagarajan,et al. Clinical next‐generation sequencing in patients with non–small cell lung cancer , 2015, Cancer.
[6] C. Cole,et al. COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .
[7] N. Rothman,et al. Comparison of yield and genotyping performance of multiple displacement amplification and OmniPlex™ whole genome amplified DNA generated from multiple DNA sources , 2005, Human mutation.
[8] Ashish Choudhary,et al. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel , 2014, BMC Medical Genomics.
[9] N. Carter,et al. Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. , 1992, Genomics.
[10] Joshua L. Deignan,et al. ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.
[11] G. Hampton,et al. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. , 2014, The oncologist.
[12] A. Oberthuer,et al. Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma , 2012, Journal of Human Genetics.
[13] N. Girard,et al. Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 , 2014, Clinical Cancer Research.
[14] R. Hubert,et al. Whole genome amplification from a single cell: implications for genetic analysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] Yu Cao,et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.
[16] C. Dooms,et al. Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study , 2014, Translational Respiratory Medicine.
[17] A. Singh,et al. Single cell genome sequencing. , 2012, Current opinion in biotechnology.
[18] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[19] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[20] Z. Szallasi,et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.
[21] Pablo Cingolani,et al. © 2012 Landes Bioscience. Do not distribute. , 2022 .
[22] T. Beaty,et al. Comparing whole-genome amplification methods and sources of biological samples for single-nucleotide polymorphism genotyping. , 2005, Clinical chemistry.
[23] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[24] M. Tsao,et al. Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.
[26] S. Antonarakis,et al. Corrigendum: Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2002, Human mutation.
[27] Sabine Tejpar,et al. Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers , 2015, PloS one.
[28] Xiuqin Jiang,et al. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer , 2014, Cancer biology & therapy.
[29] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[30] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[31] Mark B Gerstein,et al. Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing , 2006, BMC Genomics.
[32] Adam C. Marko,et al. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies , 2013, Genome Medicine.
[33] A. Ballestrero,et al. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition , 2015, Targeted Oncology.
[34] K. Shadan,et al. Available online: , 2012 .
[35] P. Lizardi,et al. Mutation detection and single-molecule counting using isothermal rolling-circle amplification , 1998, Nature Genetics.
[36] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[37] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[38] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Russell Higuchi,et al. Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions , 1993, Bio/Technology.
[40] S. Chanock,et al. Effects of DNA mass on multiple displacement whole genome amplification and genotyping performance , 2005, BMC biotechnology.
[41] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[42] J. Todd,et al. BMC Biotechnology BioMed Central Methodology article A gene expression system offering multiple levels of regulation: the Dual Drug Control (DDC) system , 2004 .
[43] Ashish Choudhary,et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.
[44] Li Ding,et al. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.
[45] Stephen J. Chanock,et al. The new sequencer on the block: comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing , 2013, Human Genetics.
[46] Wen Tan,et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.
[47] M. Wrensch,et al. DNA Quantification of Whole Genome Amplified Samples for Genotyping on a Multiplexed Bead Array Platform , 2007, Cancer Epidemiology Biomarkers & Prevention.
[48] Vladimir Makarov,et al. Use of in vitro OmniPlex libraries for high-throughput comparative genomics and molecular haplotyping , 2002, SPIE BiOS.
[49] F. Boccardo,et al. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. , 2015, Current drug targets.
[50] A. Wilm,et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets , 2012, Nucleic acids research.
[51] Roger S Lasken,et al. Unbiased whole-genome amplification directly from clinical samples. , 2003, Genome Research.
[52] H. Koong,et al. Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[53] Rita T. Lawlor,et al. DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples , 2013, PloS one.
[54] Rameen Beroukhim,et al. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. , 2004, Nucleic acids research.
[55] J. Langmore. Rubicon Genomics, Inc. , 2002, Pharmacogenomics.
[56] S. Kingsmore,et al. Comprehensive human genome amplification using multiple displacement amplification , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[57] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[58] J. Ross,et al. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. , 2011, Biomarkers in medicine.
[59] N. Lennon,et al. Characterizing and measuring bias in sequence data , 2013, Genome Biology.
[60] M. Ronaghi,et al. A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.